Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans

Alan Breier, Orlando Davis, Robert Buchanan, Samuel J. Listwak, Courtney Holmes, David Pickar, David S. Goldstein

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Concurrent effects of benzodiazepines on stress-induced activation of the three classical "stress" systems: pituitary-adrenal, adrenomedullary, and sympathoneural systems have not been extensively investigated in humans. In the present study, the effects of alprazolam (1.5 mg) on plasma levels of adrenocorticotropin hormone (ACTH), epinephrine, norepinephrine, dihydroxyphenylglycol (DHPG, the intraneuronal metabolite of norepinephrine), and mood states were examined in 10 healthy volunteers undergoing glucoprivic stress. Glucoprivic stress was induced by intravenous administration of the glucose analog, 2-deoxyglucose (2DG), at a dose (50 mg/kg) that impairs cellular glucose metabolism and produces a state comparable to hypoglycemia. Alprazolam and 2DG were administered in a double-blind, placebo-controlled manner. 2DG produced robust elevations in plasma ACTH and epinephrine levels, modest elevations in plasma norepinephrine levels, and decreases in plasma DHPG levels. Alprazolam significantly attenuated the 2DG-induced increases in plasma ACTH and epinephrine, but did not significantly effect plasma norepinephrine and DHPG. These data suggest that benzodiazepines attenuate metabolic stress-induced activation of the pituitary-adrenal and adrenomedullary systems but do not effect 2DG-related effects on peripheral sympathoneural function. The possible mechanisms involved are discussed.

Original languageEnglish (US)
Pages (from-to)880-890
Number of pages11
JournalBiological Psychiatry
Volume32
Issue number10
DOIs
StatePublished - Nov 15 1992
Externally publishedYes

Fingerprint

Alprazolam
Physiological Stress
Deoxyglucose
Norepinephrine
Pituitary-Adrenal System
Adrenocorticotropic Hormone
Epinephrine
Hormones
Benzodiazepines
Glucose
Hypoglycemia
Intravenous Administration
Healthy Volunteers
Placebos
dihydroxyphenylethylene glycol

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. / Breier, Alan; Davis, Orlando; Buchanan, Robert; Listwak, Samuel J.; Holmes, Courtney; Pickar, David; Goldstein, David S.

In: Biological Psychiatry, Vol. 32, No. 10, 15.11.1992, p. 880-890.

Research output: Contribution to journalArticle

Breier, Alan ; Davis, Orlando ; Buchanan, Robert ; Listwak, Samuel J. ; Holmes, Courtney ; Pickar, David ; Goldstein, David S. / Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. In: Biological Psychiatry. 1992 ; Vol. 32, No. 10. pp. 880-890.
@article{43c98d0ba7544edba6209a0dce1ec8aa,
title = "Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans",
abstract = "Concurrent effects of benzodiazepines on stress-induced activation of the three classical {"}stress{"} systems: pituitary-adrenal, adrenomedullary, and sympathoneural systems have not been extensively investigated in humans. In the present study, the effects of alprazolam (1.5 mg) on plasma levels of adrenocorticotropin hormone (ACTH), epinephrine, norepinephrine, dihydroxyphenylglycol (DHPG, the intraneuronal metabolite of norepinephrine), and mood states were examined in 10 healthy volunteers undergoing glucoprivic stress. Glucoprivic stress was induced by intravenous administration of the glucose analog, 2-deoxyglucose (2DG), at a dose (50 mg/kg) that impairs cellular glucose metabolism and produces a state comparable to hypoglycemia. Alprazolam and 2DG were administered in a double-blind, placebo-controlled manner. 2DG produced robust elevations in plasma ACTH and epinephrine levels, modest elevations in plasma norepinephrine levels, and decreases in plasma DHPG levels. Alprazolam significantly attenuated the 2DG-induced increases in plasma ACTH and epinephrine, but did not significantly effect plasma norepinephrine and DHPG. These data suggest that benzodiazepines attenuate metabolic stress-induced activation of the pituitary-adrenal and adrenomedullary systems but do not effect 2DG-related effects on peripheral sympathoneural function. The possible mechanisms involved are discussed.",
author = "Alan Breier and Orlando Davis and Robert Buchanan and Listwak, {Samuel J.} and Courtney Holmes and David Pickar and Goldstein, {David S.}",
year = "1992",
month = "11",
day = "15",
doi = "10.1016/0006-3223(92)90177-2",
language = "English (US)",
volume = "32",
pages = "880--890",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans

AU - Breier, Alan

AU - Davis, Orlando

AU - Buchanan, Robert

AU - Listwak, Samuel J.

AU - Holmes, Courtney

AU - Pickar, David

AU - Goldstein, David S.

PY - 1992/11/15

Y1 - 1992/11/15

N2 - Concurrent effects of benzodiazepines on stress-induced activation of the three classical "stress" systems: pituitary-adrenal, adrenomedullary, and sympathoneural systems have not been extensively investigated in humans. In the present study, the effects of alprazolam (1.5 mg) on plasma levels of adrenocorticotropin hormone (ACTH), epinephrine, norepinephrine, dihydroxyphenylglycol (DHPG, the intraneuronal metabolite of norepinephrine), and mood states were examined in 10 healthy volunteers undergoing glucoprivic stress. Glucoprivic stress was induced by intravenous administration of the glucose analog, 2-deoxyglucose (2DG), at a dose (50 mg/kg) that impairs cellular glucose metabolism and produces a state comparable to hypoglycemia. Alprazolam and 2DG were administered in a double-blind, placebo-controlled manner. 2DG produced robust elevations in plasma ACTH and epinephrine levels, modest elevations in plasma norepinephrine levels, and decreases in plasma DHPG levels. Alprazolam significantly attenuated the 2DG-induced increases in plasma ACTH and epinephrine, but did not significantly effect plasma norepinephrine and DHPG. These data suggest that benzodiazepines attenuate metabolic stress-induced activation of the pituitary-adrenal and adrenomedullary systems but do not effect 2DG-related effects on peripheral sympathoneural function. The possible mechanisms involved are discussed.

AB - Concurrent effects of benzodiazepines on stress-induced activation of the three classical "stress" systems: pituitary-adrenal, adrenomedullary, and sympathoneural systems have not been extensively investigated in humans. In the present study, the effects of alprazolam (1.5 mg) on plasma levels of adrenocorticotropin hormone (ACTH), epinephrine, norepinephrine, dihydroxyphenylglycol (DHPG, the intraneuronal metabolite of norepinephrine), and mood states were examined in 10 healthy volunteers undergoing glucoprivic stress. Glucoprivic stress was induced by intravenous administration of the glucose analog, 2-deoxyglucose (2DG), at a dose (50 mg/kg) that impairs cellular glucose metabolism and produces a state comparable to hypoglycemia. Alprazolam and 2DG were administered in a double-blind, placebo-controlled manner. 2DG produced robust elevations in plasma ACTH and epinephrine levels, modest elevations in plasma norepinephrine levels, and decreases in plasma DHPG levels. Alprazolam significantly attenuated the 2DG-induced increases in plasma ACTH and epinephrine, but did not significantly effect plasma norepinephrine and DHPG. These data suggest that benzodiazepines attenuate metabolic stress-induced activation of the pituitary-adrenal and adrenomedullary systems but do not effect 2DG-related effects on peripheral sympathoneural function. The possible mechanisms involved are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0027064948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027064948&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(92)90177-2

DO - 10.1016/0006-3223(92)90177-2

M3 - Article

C2 - 1334713

AN - SCOPUS:0027064948

VL - 32

SP - 880

EP - 890

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 10

ER -